BRCA1 and ovarian carcinoma: In the presence of heterozygous BRCA1 pathogenic variants (PV), but without associated clinical signs of FA, and in the absence of a familial history of breast or ovarian cancers, an assessment of the actual oncological risk in this patient is difficult.